Comparison of Clinical Response, Pharmacokinetics and Systems Pharmacology Between Dispersible Form of Levodopa and Mucuna pruriens Powder in Parkinson s disease

Phase 1

Recruiting

• Conditions: Parkinson' disease patients with motor complication; s disease; Mucuna pruriens

• Registration Number: TCTR20220607005
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-07
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

(1)PD patients above 18 years of age
(2)Patients who diagnose PD according to UKPDSBB criteria.
(3)Patients whose symptoms were stable and medication dosage remained same within 3 months.
(4)Patients who had motor complication at least 2 hours per day in awakening time.
(5)Patients who had ability to record PD diary.

Exclusion Criteria

(1)Patients who had H&Y stage 5 in off period.
(2)Patients who had uncontrolled psychotic symptoms .
(3)Patients who had dementia determine by TMSE score < 23.
(4)Patients who pregnant
(5)Patients who currently use drugs that interfere gastric emptying times
(6)Patients who had unstable disease such as heart disease or renal failure
(7)Patients who had diabetes
(8)Patients who allergy to leguminous plant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic 6 hours period AUC, Tmax, Cmax

Secondary Outcome Measures

Name	Time	Method
PDRS score 6 hours period UPDRS part 3